Patients play a vital role in finding better ways to treat cancer by participating in clinical trials. Thanks to patients who volunteered for studies, we now have a range of treatments that can cure or delay the progression of cancer for many years. Our patients are partners in care and partners in discovery.
As national leaders in the field, the University of Michigan Comprehensive Cancer Center's Skin Cancer Program provides care that builds on research and decades of outstanding success rates in the healing of all types of skin cancer -- melanoma, basal and squamous cell carcinomas, and Merkel cell carcinomas.
Over the past 30 years -- and through hundreds of clinical trials -- we've discovered better treatments so there's less chance of cancer coming back. With the help of clinical trials, we've also learned better methods of detecting cancer -- catching it earlier, when we have the best chance of curing it.
More than 190,000 women will be diagnosed with breast cancer this year. But only 5-10% of those breast cancers are caused by an inherited genetic mutation. The same gene can put women at a higher risk of ovarian cancer as well.
At the University of Michigan Comprehensive Cancer Center, doctors and scientists are committed to discovering new forms of treatment for head and neck cancer. By using the latest surgical techniques and incorporating the newest laboratory discoveries, we are able to preserve and rebuild the tissues of the mouth and throat so our patients can return to their daily lives with excellent function and quality of life.
Clinical research is a partnership between doctors and patients working to improve the treatment of cancer. Being in a clinical trial can mean trying new medicines to understand them better. Research can also mean comparing two types of cancer treatment to see which one is most effective. The ultimate goal of all clinical trials is to cure cancer and improve quality of life.
The collaborative spirit is at work here, allowing doctors and scientists to assist each other in advancing us toward better and more effective treatments for cancer. Be part of our progress. Be part of the Michigan Difference.
Adrenal cancer is rare. Exceptional patient care and innovative treatment strategies for adrenal cancer shouldn't be. At the University of Michigan Comprehensive Cancer Center, we apply the same multidisciplinary approach to diagnosing and treating adrenal cancer, and the same translational approach to basic and clinical research in the field, as we do for more prevalent cancer types.
Avastin, Sutent increase breast cancer stem cells, U-M study shows
The drugs Avastin and Sutent
have been looked at as potential breast cancer treatments. But while they do shrink tumors and slow the time till the cancer progresses,
the effect does not last, and the cancer eventually regrows and spreads.
Learn more!
Winter issue of THRIVE is online
This on-line publication features research and treatment articles for our patients.
New technology allows CT scans to be done with a fraction of the conventional radiation dose
Reduces cancer risk from radiation.
Natural enzyme provides potential new approach for treating graft-vs-host-disease
Alpha-1-antitrypsin reduced intense inflammation after bone marrow transplant.
Winter issue of THRIVE is online
THRIVE, our patient-focused online magazine, presents information about living life with cancer.
This month's issue offers stories on
helping children understand when their parent has cancer; the latest on which nutrition supplements are safe for people undergoing cancer
treatment; and much more! Read it!
New technology allows CT scans to be done with a fraction of the conventional radiation dose
Reduces cancer risk from radiation.
Natural enzyme provides potential new approach for treating graft-vs-host-disease
Alpha-1-antitrypsin reduced intense inflammation after bone marrow transplant.
New indicator may help identify patients with increased risk from throat cancer
Matted lymph nodes may cause cancer to spread.
New technology allows CT scans to be done with a fraction of the conventional radiation dose
Over the past decade, U-M scientists have contributed to the research behind the new GE Healthcare technology, known as Veo.
"Reducing patients' radiation exposure is a high priority for us," says Ella Kazerooni, M.D., M.S., professor of radiology at the U-M Medical School.
Learn more
Natural enzyme provides potential new approach for treating graft-vs-host-disease
Alpha-1-antitrypsin reduced intense inflammation after bone marrow transplant.
New indicator may help identify patients with increased risk from throat cancer
Matted lymph nodes may cause cancer to spread.
Software for analyzing digital pathology images proving its usefulness
Software separates malignancy from background tissue.
Natural enzyme provides potential new approach for treating graft-vs-host-disease
A natural enzyme derived from human blood plasma showed potential in significantly reducing the
effects of graft-vs.-host disease, a side effect of lifesaving bone marrow transplants. This drug -- which is already
approved by the FDA, has been used by many patients over extended periods of time and causes few side effects.
Learn more
New indicator may help identify patients with increased risk from throat cancer
Matted lymph nodes may cause cancer to spread.
Software for analyzing digital pathology images proving its usefulness
Software separates malignancy from background tissue.
January is Cervical Cancer Awareness Month
Find out risks associated with this disease.
